AMRX Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of 2.31% compared to Amneal Pharmaceuticals, Inc.'s net margin of 33.55%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat Amgen, Inc.'s return on equity of 95.55%.

Amneal Pharmaceuticals, Inc. has a consensus price target of $13.50, signalling upside risk potential of 13.07%. On the other hand Amgen, Inc. has an analysts' consensus of $324.25 which suggests that it could fall by -4.68%. Given that Amneal Pharmaceuticals, Inc. has higher upside potential than Amgen, Inc., analysts believe Amneal Pharmaceuticals, Inc. is more attractive than Amgen, Inc..

Amneal Pharmaceuticals, Inc. has a beta of 1.365, which suggesting that the stock is 36.493% more volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.

Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.8% to investors and pays a quarterly dividend of $2.38 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.

Amneal Pharmaceuticals, Inc. quarterly revenues are $784.5M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Amneal Pharmaceuticals, Inc.'s net income of $18.1M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 846.81x while Amgen, Inc.'s PE ratio is 26.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.30x versus 5.13x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 2.31% compared to Amneal Pharmaceuticals, Inc.'s net margin of 21.47%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat Johnson & Johnson's return on equity of 33.27%.

Amneal Pharmaceuticals, Inc. has a consensus price target of $13.50, signalling upside risk potential of 13.07%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could grow by 0.03%. Given that Amneal Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Amneal Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

Amneal Pharmaceuticals, Inc. has a beta of 1.365, which suggesting that the stock is 36.493% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.54% to investors and pays a quarterly dividend of $1.30 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amneal Pharmaceuticals, Inc. quarterly revenues are $784.5M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Amneal Pharmaceuticals, Inc.'s net income of $18.1M is lower than Johnson & Johnson's net income of $5.2B. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 846.81x while Johnson & Johnson's PE ratio is 19.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.30x versus 5.33x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics Corp. has a net margin of 2.31% compared to Amneal Pharmaceuticals, Inc.'s net margin of 42.36%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat United Therapeutics Corp.'s return on equity of 19.2%.

Amneal Pharmaceuticals, Inc. has a consensus price target of $13.50, signalling upside risk potential of 13.07%. On the other hand United Therapeutics Corp. has an analysts' consensus of $518.25 which suggests that it could grow by 7.06%. Given that Amneal Pharmaceuticals, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Amneal Pharmaceuticals, Inc. is more attractive than United Therapeutics Corp..

Amneal Pharmaceuticals, Inc. has a beta of 1.365, which suggesting that the stock is 36.493% more volatile than S&P 500. In comparison United Therapeutics Corp. has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.874%.

Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. United Therapeutics Corp. pays out -- of its earnings as a dividend.

Amneal Pharmaceuticals, Inc. quarterly revenues are $784.5M, which are smaller than United Therapeutics Corp. quarterly revenues of $799.5M. Amneal Pharmaceuticals, Inc.'s net income of $18.1M is lower than United Therapeutics Corp.'s net income of $338.7M. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 846.81x while United Therapeutics Corp.'s PE ratio is 18.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.30x versus 7.46x for United Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Xeris Biopharma Holdings, Inc. has a net margin of 2.31% compared to Amneal Pharmaceuticals, Inc.'s net margin of 0.84%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat Xeris Biopharma Holdings, Inc.'s return on equity of -1019.2%.

Amneal Pharmaceuticals, Inc. has a consensus price target of $13.50, signalling upside risk potential of 13.07%. On the other hand Xeris Biopharma Holdings, Inc. has an analysts' consensus of $11.50 which suggests that it could grow by 71.13%. Given that Xeris Biopharma Holdings, Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Xeris Biopharma Holdings, Inc. is more attractive than Amneal Pharmaceuticals, Inc..

Amneal Pharmaceuticals, Inc. has a beta of 1.365, which suggesting that the stock is 36.493% more volatile than S&P 500. In comparison Xeris Biopharma Holdings, Inc. has a beta of 0.667, suggesting its less volatile than the S&P 500 by 33.307%.

Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xeris Biopharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Xeris Biopharma Holdings, Inc. pays out -- of its earnings as a dividend.

Amneal Pharmaceuticals, Inc. quarterly revenues are $784.5M, which are larger than Xeris Biopharma Holdings, Inc. quarterly revenues of $74.4M. Amneal Pharmaceuticals, Inc.'s net income of $18.1M is higher than Xeris Biopharma Holdings, Inc.'s net income of $621K. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 846.81x while Xeris Biopharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.30x versus 4.03x for Xeris Biopharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.